Clinical trial NCT05618509: Immediate Effects of STENDO on the Walking Abilities of Patients with COPD (STENDO-COPD)
Official title: Immediate Effects of STENDO on the Walking Abilities of Patients with COPD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Walking Performance
Lead sponsor: Elsan
Sponsor class: OTHER
Collaborators: name: European Clinical Trial Experts Network
First posted: 2022-11-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The STENDO process is a heart rate synchronized massage system initially validated for the treatment of lymphedema. It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. This technique would also allow an improvement of endothelial function by a greater release of nitric oxide. Thus the capacity for physical exercise is potentially improved.

The use of STENDO has never been evaluated in COPD (Chronic obstructive pulmonary disease) where physical capacity is impaired with, in particular, the presence of endothelial dysfunction. STENDO may improve walking performance. If these hypotheses are validated, the STENDO could be positioned as a complement to the exercise rehabilitation strategies offered to symptomatic COPD patients.


Eligibility criteria: Inclusion Criteria:

* Symptomatic chronic obstructive pulmonary disease (COPD) attested by a Tiffeneau ratio \<70%
* Not oxygen dependent
* Oriented for an ambulatory effort rehabilitation program in after-care and rehabilitation
* Negative urine pregnancy test in women of childbearing age
* Affiliation to a social security scheme or beneficiary of such a scheme
* Patient having signed the free and informed consent

Exclusion Criteria:

* Neurological or osteo-articular pathology impeding walking.
* Dementia with MMSE (Mini mental state examination) \<24/30
* Heart failure
* Covid + in the previous 3 months
* Major surgery in the year preceding the session
* Heavy abdominal, pelvic and lower limb cosmetic surgery in the year preceding the session
* Impaired comprehension and/or expression
* Being simultaneously on oral contraception (pill) and smoking (more than 10 cigarettes per day)
* Severe unbalanced high blood pressure
* severe peripheral neuropathy
* Colostomy
* Open fracture, bleeding or healing wound
* 3rd degree burn
* Liver cirrhosis
* Bedsore
* Have prohibitions and restrictions with a history of phlebitis or recent progressive venous thrombosis (less than 6 months) or arterial disease of the lower limbs stage 3 and 4
* Refusal to participate in the study

Primary outcomes:
measure: Variation in the 6-minute walk test distance after the performance of the STENDO/STENDO Placebo session compared to the value of the initial 6-minute walk test..
timeFrame: Baseline to immediately after STENDO/STENDO Placebo procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Tarbes
country: France
facility: Polyclinique de l'Ormeau
Study officials:
References: